Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebes...

Holo, a fintech platform reinventing how people buy homes in the UAE, has announced that it has raised $22 million in one of the largest Series A rounds in the GCC in 2025. The investment round was led by Saudi Arabia’s Impact46, with support from Mubadala Investment Company “Mubadala”, an Abu Dhabi sovereign investor, and participation from Rua Growth Fund, anb seed, MoreThan Capital, and returning investors Salica Oryx Fund and Dubai Future District Fund. This press release features multimed...